SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

NAN Nanosonics Limited

Healthcare · Medical Instruments & Supplies · website · 508 employees
$2.88
52wk 2.64 – 4.76
Overall
45.4
Value
14.3
Growth
69.2
Health
85.2
Quality
42.0
Momentum
5.5
Dividend
—
Price
About Nanosonics Limited

Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In addition, it is involved in the research, development, and commercialization of the CORIS system, an automated technology designed to transform flexible endoscope reprocessing. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Price analytics

Returns

1 day 0.3%
1 week -2.4%
1 month 4.7%
3 months -14.5%
6 months -25.6%
1 year -33.8%
3 years -30.3%

Risk

Volatility (1y ann.) 40.8%
Beta vs ASX 200 0.64
Sharpe (1y) -0.90
VaR 95% (1-day) -4.1%
Max drawdown (1y) -43.6%
Off 1-year high -39.1%

Technicals

RSI(14) 57
vs 50DMA -7.0%
vs 200DMA -16.0%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 14.3
Trailing P/E
0
Forward P/E
0
PEG ratio
0
EV / EBITDA
0
Price / Book
56
Price / Sales
63
Growth 69.2
Revenue growth (1y)
36
Revenue CAGR (3y)
47
EPS growth (1y)
100
EPS CAGR (3y)
100
Financial Health 85.2
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
33
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow) 42.0
Return on equity
42
Return on assets
37
Operating margin
31
Net margin
58
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 5.5
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
15
Position in 52-week range
11

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$861.60M
P/E (trailing)
48.00
P/E (forward)
55.38
EPS (trailing)
0.06
Dividend yield
—
Payout ratio
0.0%
Beta
1.19
EV / EBITDA
32.96
Price / Book
3.96
ROE
8.3%
Operating margin
7.7%
Net margin
8.7%
Total cash
$155.22M
Total debt
$23.13M
Current ratio
5.56
Debt / Equity
0.11
Free cash flow
$-72,375
Avg volume
896,012
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$203.89M
  • Gross profit$156.81M
  • Operating income$6.70M
  • Net income$17.84M
  • Diluted EPS—
  • Free cash flow$17.41M
  • Net debt-$132.09M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4